GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Share Price Chart
GlaxoSmithKline Pharmaceuticals last traded at ₹2,524.20 (2026-10-13). Over the past month the stock moved -11.1%, three months the stock moved +10.6%, year the stock moved -7.8%. Its closing range over 52 weeks is ₹2,259.20 – ₹3,105.00, with the latest close 18.7% below the high.
Closing prices up to 2026-10-13.
About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Leading Global Health care company:[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham and is the world’s sixth-largest pharmaceutical company.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), GlaxoSmithKline Pharmaceuticals reported sales of ₹938.00 crore (+16.5%) and net profit of ₹237.00 crore (+15.6%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 938.00 | 296.00 | 31.00 | 237.00 | 14.00 |
| Mar 2026 | 995.00 | 351.00 | 35.00 | 278.00 | 16.40 |
| Dec 2025 | 1,041 | 371.00 | 36.00 | 296.00 | 17.45 |
| Sep 2025 | 980.00 | 336.00 | 34.00 | 257.00 | 15.20 |
| Jun 2025 | 805.00 | 251.00 | 31.00 | 205.00 | 12.10 |
| Mar 2025 | 974.00 | 333.00 | 34.00 | 263.00 | 15.52 |
| Dec 2024 | 949.00 | 292.00 | 31.00 | 230.00 | 13.57 |
| Sep 2024 | 1,011 | 322.00 | 32.00 | 252.00 | 14.91 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +5.6% | +17.9% | +4.7% | -1.2% | -3.1% | +9.7% | +2.2% | +16.5% |
| Operating profit growth | +11.4% | +33.9% | +29.6% | +8.7% | +4.3% | +27.1% | +5.4% | +17.9% |
| Net profit growth | +15.6% | +400.0% | +35.6% | +12.6% | +2.0% | +28.7% | +5.7% | +15.6% |
| EPS growth | +16.1% | +402.6% | +35.2% | +12.5% | +1.9% | +28.6% | +5.7% | +15.7% |
| OPM % | 32.0% | 31.0% | 34.0% | 31.0% | 34.0% | 36.0% | 35.0% | 31.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), GlaxoSmithKline Pharmaceuticals reported sales of ₹3,822.00 crore (+1.9%) and net profit of ₹1,036.00 crore (+11.6%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 3,822 | 1,309 | 34.00 | 1,036 | 61.15 |
| Mar 2025 | 3,749 | 1,179 | 31.00 | 928.00 | 54.75 |
| Mar 2024 | 3,454 | 909.00 | 26.00 | 590.00 | 34.83 |
| Mar 2023 | 3,252 | 804.00 | 25.00 | 611.00 | 36.05 |
| Mar 2022 | 3,278 | 762.00 | 23.00 | 1,695 | 100.04 |
| Mar 2021 | 2,926 | 598.00 | 20.00 | 358.00 | 21.14 |
| Mar 2020 | 3,224 | 657.00 | 20.00 | 93.00 | 5.50 |
| Mar 2019 | 3,128 | 601.00 | 19.00 | 445.00 | 26.29 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +9.0% | +3.1% | -9.2% | +12.0% | -0.8% | +6.2% | +8.5% | +1.9% |
| Operating profit growth | +18.3% | +9.3% | -9.0% | +27.4% | +5.5% | +13.1% | +29.7% | +11.0% |
| Net profit growth | +26.8% | -79.1% | +284.9% | +373.5% | -64.0% | -3.4% | +57.3% | +11.6% |
| EPS growth | +27.0% | -79.1% | +284.4% | +373.2% | -64.0% | -3.4% | +57.2% | +11.7% |
| OPM % | 19.0% | 20.0% | 20.0% | 23.0% | 25.0% | 26.0% | 31.0% | 34.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for GlaxoSmithKline Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
Volumes jump at Glaxosmithkline Pharmaceuticals Ltd counter - Business Standard
-
GlaxoSmithKline Pharmaceuticals shares rise 2.04% in today's trade - Moneycontrol.com
-
GlaxoSmithKline Pharmaceuticals shares rise 2.04% in today's trade - Moneycontrol.com
-
GlaxoSmithKline Pharmaceuticals shares climb over 2% to Rs 2,668 - Moneycontrol.com
-
Glaxosmithkline Pharmaceuticals Ltd Live Stock Price , Glaxo Live Share Price, 500660 - BSE India
-
Glaxosmithkline Pharmaceuticals Ltd Latest Corporate Announcements, Glaxo Latest Company News - BSE India
-
GlaxoSmithKline Pharmaceuticals Reports Strong FY26 Results; Board Recommends Rs. 57 Per Share Final Dividend - scanx.trade
-
Glaxosmithkline Pharmaceuticals Ltd Latest Corporate Announcements, Glaxo Latest Company News - BSE India
-
GlaxoSmithKline Pharmaceuticals Reports Strong FY26 Results; Board Recommends Rs. 57 Per Share Final Dividend - scanx.trade
Frequently Asked Questions
What is the share price of GlaxoSmithKline Pharmaceuticals today?
GlaxoSmithKline Pharmaceuticals shares were last quoted at ₹2,524.20 (-0.6% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals has a price-to-earnings (P/E) ratio of 45.96 and a price-to-book (P/B) ratio of 19.60. The industry P/E is 53.33.
What is the 52-week high and low of GlaxoSmithKline Pharmaceuticals?
The 52-week high of GlaxoSmithKline Pharmaceuticals is ₹3,121.10 and the 52-week low is ₹2,088.00.
What is the market cap of GlaxoSmithKline Pharmaceuticals?
The market capitalisation of GlaxoSmithKline Pharmaceuticals is about ₹49,091.33 crore.
How did GlaxoSmithKline Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), GlaxoSmithKline Pharmaceuticals reported sales of ₹938.00 crore (+16.5%) and net profit of ₹237.00 crore (+15.6%), compared with the same quarter last year.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, GlaxoSmithKline Pharmaceuticals has a 3-year ROE of 43.00%, 3-year profit growth of 18.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in GlaxoSmithKline Pharmaceuticals?
Promoters hold about 75.00% of GlaxoSmithKline Pharmaceuticals.
Which sector does GlaxoSmithKline Pharmaceuticals belong to?
GlaxoSmithKline Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.